Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 5
1978 3
1982 1
1983 2
1984 3
1986 2
1987 2
1988 2
1989 2
1990 5
1991 4
1992 5
1993 4
1994 3
1995 7
1996 5
1997 4
1998 6
1999 6
2000 10
2001 7
2002 6
2003 8
2004 4
2005 7
2006 6
2007 10
2008 11
2009 11
2010 11
2011 10
2012 8
2013 12
2014 14
2015 28
2016 14
2017 12
2018 10
2019 4
2020 6
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Results by year

Filters applied: . Clear all
Page 1
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J. Morschhauser F, et al. Among authors: press ow. Lancet Haematol. 2019 May;6(5):e254-e265. doi: 10.1016/S2352-3026(19)30026-2. Epub 2019 Mar 29. Lancet Haematol. 2019. PMID: 30935953 Clinical Trial.
Immunotoxins.
Press OW. Press OW. Biotherapy. 1991;3(1):65-76. doi: 10.1007/BF02175100. Biotherapy. 1991. PMID: 2009215 Review.
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F. Palanca-Wessels MC, et al. Among authors: press ow. Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27. Lancet Oncol. 2015. PMID: 25925619 Clinical Trial.
Radioimmunotherapy of human tumours.
Larson SM, Carrasquillo JA, Cheung NK, Press OW. Larson SM, et al. Among authors: press ow. Nat Rev Cancer. 2015 Jun;15(6):347-60. doi: 10.1038/nrc3925. Nat Rev Cancer. 2015. PMID: 25998714 Free PMC article. Review.
Whither Radioimmunotherapy: To Be or Not To Be?
Green DJ, Press OW. Green DJ, et al. Among authors: press ow. Cancer Res. 2017 May 1;77(9):2191-2196. doi: 10.1158/0008-5472.CAN-16-2523. Epub 2017 Apr 20. Cancer Res. 2017. PMID: 28428282 Free PMC article. Review.
Immunotherapy of Non-Hodgkin's lymphomas.
Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Press OW, et al. Hematology Am Soc Hematol Educ Program. 2001:221-40. doi: 10.1182/asheducation-2001.1.221. Hematology Am Soc Hematol Educ Program. 2001. PMID: 11722986 Review.
Pretargeted radioimmunotherapy for B-cell lymphomas.
Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur DS, Gopal A, Hamlin DK, Press OW. Green DJ, et al. Among authors: press ow. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5598s-5603s. doi: 10.1158/1078-0432.CCR-07-1223. Clin Cancer Res. 2007. PMID: 17875795 Review.
Clinical applications of anti-CD20 antibodies.
Gopal AK, Press OW. Gopal AK, et al. Among authors: press ow. J Lab Clin Med. 1999 Nov;134(5):445-50. doi: 10.1016/s0022-2143(99)90164-6. J Lab Clin Med. 1999. PMID: 10560936 Review. No abstract available.
257 results